|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
27.04.26 - 09:12
|
Astellas Pharma Inc. Profit Rises In Full Year (AFX)
|
|
|
TOKYO (dpa-AFX) - Astellas Pharma Inc. (ALPMY) announced earnings for its full year that Increased, from the same period last yearThe company's earnings came in at JPY291.535 billion, or JPY162.22......
|
|
|
21.04.26 - 12:24
|
Pfizer and Astellas secure FDA priority review for Padcev MIBC combo therapy (PBR)
|
|
|
The application aims to allow the use of this combination therapy for all patients with MIBC, regardless of their cisplatin eligibility. It could potentially broaden the approved use,
The post Pfizer and Astellas secure FDA priority review for Padcev MIBC combo therapy appeared first on Pharmaceutical Business review....
|
|
|
|
|
|
|
08.04.26 - 13:06
|
Sidewinder Therapeutics Announces $137 Million Series B Financing to Advance Precision Bispecific ADCs into Clinical Development for Cancer (Business Wire)
|
|
|
Financing co-led by Frazier Life Sciences and Novartis Venture Fund with significant participation from OrbiMed, Life Sciences at Goldman Sachs Alternatives, DCVC Bio, Samsara BioCapital, Longwood Fund and Astellas Venture ManagementSAN DIEGO--(BUSINESS WIRE)--Sidewinder Therapeutics, a biopharmaceutical company pioneering the development of next-generation bispecific ADCs (antibody-drug conjugates) for the treatment of cancer, today announced the closing of an oversubscribed $137 million Series B financing. The round was co-led by Frazier Life Sciences and Novartis Venture Fund, with participation from the sole Series A investor OrbiMed as well as new investors including Life Sciences at Goldman Sachs Alternatives, DCVC Bio, Samsara BioCapital, Longwood Fund, Astellas Venture Management and Alexandria Venture Investments. Concurrent with the financing, Daniel Estes, Ph.D., from Frazier Life Sciences, Michal Silverberg from Novartis Venture Fund, Josh Richardson, M.D., from Life Sciences at Goldman Sachs ...
|
|
|
|
|
|
|
|
|
24.02.26 - 11:15
|
Vir Biotechnology +70%: Deal-Überraschung mit Ansage (Sharedeals)
|
|
|
Die Aktie von Vir Biotechnology ist vorbörslich um rund 70 Prozent nach oben geschossen. Auslöser der Kursexplosion ist vor allem ein milliardenschwerer Kooperationsdeal mit dem japanischen Pharmakonzern Astellas, den das Unternehmen parallel zu seinen Jahreszahlen vorgestellt hat – und der von Investoren als strategischer Wendepunkt interpretiert wird. Wegweisender Pharma-Deal Im Zentrum des neuesten Geschäftsberichts steht […]
The post Vir Biotechnology +70%: Deal-Überraschung mit Ansage first appeared on sharedeals.de....
|
|
|
|
|
|
|
23.02.26 - 23:15
|
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results (Business Wire)
|
|
|
– Announces global strategic collaboration with Astellas to advance PSMA-targeted PRO-XTEN® dual-masked T-cell engager (TCE) VIR-5500 for the treatment of prostate cancer
– Reports updated VIR-5500 Phase 1 dose-escalation data supporting a favorable safety profile and promising anti-tumor activity
– Strong financial position with $781.6 million in cash and investments as of December 31, 2025
– Conference call scheduled for February 23, 2026, at 5:30 p.m. ET / 2:30 p.m. PTSAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2025.
“This is a seminal moment for Vir Biotechnology, marked by key high-potential partnerships on two of our programs showcasing the strength of our pipeline and technology platforms. Today, we announced a global strategic collaboration with Astellas and compelling new Phase 1 data for VIR-5500, demonstrating the potential for our PRO-XT...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
